Regencell Bioscience Holdings (RGC) Equity Average (2021 - 2025)

Regencell Bioscience Holdings has reported Equity Average for 5 years, with the latest figure at $3.0 million in Q4 2025.

• For the quarter ending Q4 2025, Equity Average changed N/A year-over-year to $3.0 million; the trailing twelve-month figure through Dec 2025 stood at $3.0 million (changed N/A YoY), and the FY2025 full-year result was $6.5 million, down 35.28% from the prior year.
• Equity Average for Q4 2025 stood at $3.0 million, down from $6.5 million in the prior quarter.
• The five-year high for Equity Average was $14.5 million in Q2 2023, with the low at -$3.3 million in Q2 2021.
• Historically, Equity Average has averaged $6.2 million across 5 years, with a median of $6.5 million in 2022.
• Annual changes were most pronounced in 2022 — Equity Average jumped 296.78% — and 2025, when it sank 35.28%.
• Regencell Bioscience Holdings' Equity Average stood at -$3.3 million in 2021, then jumped by 296.78% to $6.5 million in 2022, then soared by 122.19% to $14.5 million in 2023, then plunged by 30.49% to $10.1 million in 2024, then slumped by 69.91% to $3.0 million in 2025.
• The last three Equity Average figures came in at $3.0 million (Q4 2025), $6.5 million (Q2 2025), and $10.1 million (Q2 2024), per Business Quant data.